In the ongoing process of improving PD-1/PD-L1 NSCLC immunotherapy, it will be beneficial to decipher the mechanisms regulating PD-L1 expression to identify new treatment options and biomarkers for the identification of actual immunotherapy responders among NSCLC patients. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.